262 related articles for article (PubMed ID: 29104507)
1. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
Lei H; Deng CX
Int J Biol Sci; 2017; 13(9):1163-1171. PubMed ID: 29104507
[TBL] [Abstract][Full Text] [Related]
2. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling.
Wei W; Liu W; Cassol CA; Zheng W; Asa SL; Ezzat S
Mol Cell Biol; 2012 Nov; 32(22):4662-73. PubMed ID: 22988296
[TBL] [Abstract][Full Text] [Related]
3. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
Moffa AB; Tannheimer SL; Ethier SP
Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.
Huijts PE; van Dongen M; de Goeij MC; van Moolenbroek AJ; Blanken F; Vreeswijk MP; de Kruijf EM; Mesker WE; van Zwet EW; Tollenaar RA; Smit VT; van Asperen CJ; Devilee P
Breast Cancer Res; 2011 Jul; 13(4):R72. PubMed ID: 21767389
[TBL] [Abstract][Full Text] [Related]
5. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.
Moffa AB; Ethier SP
J Cell Physiol; 2007 Mar; 210(3):720-31. PubMed ID: 17133345
[TBL] [Abstract][Full Text] [Related]
6. Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways.
Yang ZQ; Moffa AB; Haddad R; Streicher KL; Ethier SP
Int J Cancer; 2007 Sep; 121(6):1265-73. PubMed ID: 17520678
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis.
Huang YL; Chou WC; Hsiung CN; Hu LY; Chu HW; Shen CY
Hum Mol Genet; 2015 Jun; 24(12):3506-17. PubMed ID: 25788520
[TBL] [Abstract][Full Text] [Related]
8. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
9. Activating somatic FGFR2 mutations in breast cancer.
Reintjes N; Li Y; Becker A; Rohmann E; Schmutzler R; Wollnik B
PLoS One; 2013; 8(3):e60264. PubMed ID: 23527311
[TBL] [Abstract][Full Text] [Related]
10. Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Lei JH; Lee MH; Miao K; Huang Z; Yao Z; Zhang A; Xu J; Zhao M; Huang Z; Zhang X; Chen S; Jiaying NG; Feng Y; Xing F; Chen P; Sun H; Chen Q; Xiang T; Chen L; Xu X; Deng CX
Adv Sci (Weinh); 2021 Nov; 8(21):e2100974. PubMed ID: 34514747
[TBL] [Abstract][Full Text] [Related]
11. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.
Kondo T; Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2007 Aug; 13(16):4713-20. PubMed ID: 17699848
[TBL] [Abstract][Full Text] [Related]
12. FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells.
Turczyk L; Kitowska K; Mieszkowska M; Mieczkowski K; Czaplinska D; Piasecka D; Kordek R; Skladanowski AC; Potemski P; Romanska HM; Sadej R
Neoplasia; 2017 Oct; 19(10):791-804. PubMed ID: 28869838
[TBL] [Abstract][Full Text] [Related]
13. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
14. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
15. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Tanizaki J; Ercan D; Capelletti M; Dodge M; Xu C; Bahcall M; Tricker EM; Butaney M; Calles A; Sholl LM; Hammerman PS; Oxnard GR; Wong KK; Jänne PA
Cancer Res; 2015 Aug; 75(15):3139-46. PubMed ID: 26048680
[TBL] [Abstract][Full Text] [Related]
16. Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
Dankova Z; Zubor P; Grendar M; Kapinova A; Zelinova K; Jagelkova M; Gondova A; Dokus K; Kalman M; Lasabova Z; Danko J
Gen Physiol Biophys; 2017 Dec; 36(5):565-572. PubMed ID: 29372690
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Byron SA; Gartside MG; Wellens CL; Goodfellow PJ; Birrer MJ; Campbell IG; Pollock PM
Gynecol Oncol; 2010 Apr; 117(1):125-9. PubMed ID: 20106510
[TBL] [Abstract][Full Text] [Related]
18. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer.
Zhu X; Asa SL; Ezzat S
Mol Endocrinol; 2009 Sep; 23(9):1397-405. PubMed ID: 19497954
[TBL] [Abstract][Full Text] [Related]
19. Master regulators of FGFR2 signalling and breast cancer risk.
Fletcher MN; Castro MA; Wang X; de Santiago I; O'Reilly M; Chin SF; Rueda OM; Caldas C; Ponder BA; Markowetz F; Meyer KB
Nat Commun; 2013; 4():2464. PubMed ID: 24043118
[TBL] [Abstract][Full Text] [Related]
20. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
